Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature

Immune checkpoint inhibitors (ICIs), including nivolumab, have exhibited substantial benefits in the treatment of several types of cancers. However, treatment with ICIs is often accompanied by immune-related adverse events (irAEs), and a clear understanding of the precise indications and management...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Hiroki, Kodani, Masahiro, Kurai, Jun, Takeda, Kenichi, Okazaki, Ryota, Yamane, Kohei, Teruya, Yasuhiko, Yamamoto, Akihiro, Sueda, Yuriko, Yanai, Masaaki, Tanaka, Natsumi, Sakamoto, Tomohiro, Yamaguchi, Kosuke, Makino, Haruhiko, Igishi, Tadashi, Yamasaki, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781813/
https://www.ncbi.nlm.nih.gov/pubmed/31616560
http://dx.doi.org/10.3892/mco.2019.1923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781813/
https://www.ncbi.nlm.nih.gov/pubmed/31616560
http://dx.doi.org/10.3892/mco.2019.1923

Ejemplares similares